- Home
- FIHL vs AKRO Comparison
FIHL vs AKRO Comparison
Compare FIHL & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIHL
- AKRO
- Stock Information
- Founded
- FIHL 2014
- AKRO 2017
- Country
- FIHL Bermuda
- AKRO United States
- Employees
- FIHL N/A
- AKRO N/A
- Industry
- FIHL
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- FIHL
- AKRO Health Care
- Exchange
- FIHL Nasdaq
- AKRO Nasdaq
- Market Cap
- FIHL 2.1B
- AKRO 2.1B
- IPO Year
- FIHL 2023
- AKRO 2019
- Fundamental
- Price
- FIHL $17.43
- AKRO $31.59
- Analyst Decision
- FIHL Buy
- AKRO Strong Buy
- Analyst Count
- FIHL 9
- AKRO 7
- Target Price
- FIHL $20.50
- AKRO $43.20
- AVG Volume (30 Days)
- FIHL 302.1K
- AKRO 441.5K
- Earning Date
- FIHL 11-12-2024
- AKRO 11-11-2024
- Dividend Yield
- FIHL 2.30%
- AKRO N/A
- EPS Growth
- FIHL N/A
- AKRO N/A
- EPS
- FIHL 3.82
- AKRO N/A
- Revenue
- FIHL $2,151,300,000.00
- AKRO N/A
- Revenue This Year
- FIHL N/A
- AKRO N/A
- Revenue Next Year
- FIHL $13.62
- AKRO N/A
- P/E Ratio
- FIHL $4.55
- AKRO N/A
- Revenue Growth
- FIHL N/A
- AKRO N/A
- 52 Week Low
- FIHL $11.55
- AKRO $11.36
- 52 Week High
- FIHL $20.53
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- FIHL 46.22
- AKRO 66.34
- Support Level
- FIHL $17.24
- AKRO $29.34
- Resistance Level
- FIHL $17.74
- AKRO $32.15
- Average True Range (ATR)
- FIHL 0.34
- AKRO 1.26
- MACD
- FIHL -0.04
- AKRO 0.10
- Stochastic Oscillator
- FIHL 28.79
- AKRO 99.74
About FIHL Fidelis Insurance Holdings Limited
Fidelis Insurance Holdings Ltd is a global (re)insurance company. It classify the business into three underwriting segments, namely Bespoke, Specialty and Reinsurance. Specialty primarily comprises property D&F, energy, marine and aviation lines. Bespoke primarily comprises credit and political risk and other tailored solutions for clients including transactional liabilities and credit insurance. Reinsurance primarily comprises property reinsurance.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.